Journal
VETERINARY PARASITOLOGY
Volume 195, Issue 3-4, Pages 272-285Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.vetpar.2013.04.008
Keywords
Fasciola hepatica; Immunotherapeutics; Immunomodulation; Secretory proteins; Cathepsin L; Peroxiredoxin; Helminth defence molecules
Categories
Funding
- Canadian Institute of Health Research (CIHR)
- National Science and Engineering Council (NSERC)
- Ministere de l'Enseignement Superieur, de la Recherche, de la Science et de la Technologie, Quebec
- i3 Institute postdoctoral fellowship
- Programme for Research in Third Level Institutions (PRTLI) Cycle 4
- European Regional Development Fund (ERDF), part of the European Union Structural Funds Programme
- COST Action [BM1007]
Ask authors/readers for more resources
The liver fluke, Fasciola hepatica, causes fascioliasis in domestic animals (sheep, cattle), a global disease that is also an important infection of humans. As soon as the parasite invades the gut wall its interaction with various host immune cells (e.g. dendritic cells, macrophages and mast cells) is complex. The parasite secretes a myriad of molecules that direct the immune response towards a favourable non-protective Th2-mediate/regulatory environment. These immunomodulatory molecules, such as cathepsin L peptidase (FhCL1), are under development as the first generation of fluke vaccines. However, this peptidase and other molecules, such as peroxiredoxin (FhPrx) and helminth defence molecule (FhHDM-1), exhibit various immunomodulatory properties that could be harnessed to help treat immune-related conditions in humans and animals. (C) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available